Advances in antifungal therapy for onchomycosis: a focus on emerging agents and technologies
Abstract
Onychomycosis, a persistent fungal infection of the nails, is a therapeutic challenge because of its high recurrence, poor drug penetration, and resistance developed by the fungus to common antifungals (AFs). “The available therapies, such as oral azoles and topicals, can have limited efficacy, lengthy duration of treatment, or potential side effects,” they added. This has created a demand for new and better AF tactics. Novel AFs whose development has been fueled by recent advances in our understanding about fungal biology are the newer (most are second-line for invasive mycoses) broad-spectrum systemic agents with superior pharmacokinetic profiles and lower toxicities, as seen with improved azole derivatives and allylamines. Systemic AF therapy nanotechnology-mediated drug delivery systems, such as nanoparticle encapsulated AFs and liposomal formulations, have promising potential for increased drug penetration and therapeutic efficacy. In resistant cases, non-pharmacological measures such as photodynamic therapy and lasers are increasingly being considered. In addition, emerging approaches, such as microbiome-targeted interventions and RNA-based treatments, provide new methods for addressing fungal biofilms and recalcitrant infections. However, significant challenges exist in the translation of these novel therapies into clinical practice, and research efforts continue to be made toward refining modifications of treatment algorithms and enhancing patient efficacy. The…
Read the paper
Related studies
- The potential role and mechanism of circRNA/miRNA axis in cholesterol synthesis
- Updated Perspectives on the Diagnosis and Management of Onychomycosis
- Onychomycosis: Old and New
- Review of the alternative therapies for onychomycosis and superficial fungal infections: posaconazole, fosravuconazole, voriconazole, oteseconazole
- Terbinafine resistance in Trichophyton mentagrophytes and Trichophyton rubrum in the Czech Republic: A prospective multicentric study
- New drug approvals for 2022: Synthesis and clinical applications
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.